2022年套细胞淋巴瘤:分子发病机制、风险分层、临床方法及当前与新型治疗的全面更新
套细胞淋巴瘤(MCL)领域因分子发病机制、预后判断和新型治疗的进展而取得显著进步。MCL包含一系列临床亚型,罕见非典型细胞周期蛋白D1阴性MCL和原位MCL肿瘤。通过识别体细胞突变、甲基化状态、染色质组织模式、SOX-11表达、微小残留病和基因组聚类,预后判断得到进一步细化。淋巴组织微环境研究证实了B细胞受体信号、核因子κB、集落刺激因子1、CD70-SOX-11轴的作用。已鉴定出耐药分子机制、突变动态和致病通路。治疗选择从传统化学免疫治疗和干细胞移植到靶向治疗、细胞治疗和双特异性抗体。MCL患者常复发,BTK/Bcl2抑制剂和CAR-T治疗后进展(三重耐药MCL)的管理仍是挑战。
要点
- MCL由一系列临床亚型组成,罕见非典型细胞周期蛋白D1阴性MCL和原位MCL肿瘤。
- 预后判断通过识别体细胞突变(如TP53、NSD2、KMT2D)、甲基化状态、染色质组织模式、SOX-11表达、微小残留病和基因组聚类进一步细化。
- 治疗选择从传统化学免疫治疗和干细胞移植到靶向治疗(BTK共价和非共价抑制剂、Bcl2、ROR1)、细胞治疗(抗CD19 CAR-T)和针对CD19和CD20的双特异性抗体。
核心结论
- MCL领域因分子发病机制、预后判断和新型治疗的进展而取得显著进步。
- MCL患者常复发,BTK/Bcl2抑制剂和CAR-T治疗后进展(三重耐药MCL)的管理仍是挑战。
- 结合新型药物和同期转化与分子研究的下一代临床试验正在进行中。
研究设计与样本
- 综述,检索范围未报告。
主要发现
- MCL包含一系列临床亚型,罕见非典型细胞周期蛋白D1阴性MCL和原位MCL肿瘤。
- 预后判断通过识别体细胞突变(如TP53、NSD2、KMT2D)、甲基化状态、染色质组织模式、SOX-11表达、微小残留病和基因组聚类进一步细化。
- 淋巴组织微环境研究证实了B细胞受体信号、核因子κB(NF-kB)、集落刺激因子(CSF)-1、CD70-SOX-11轴的作用。
- 已鉴定出耐药分子机制、突变动态和致病通路(B细胞受体、氧化磷酸化和MYC)介导对各种治疗(布鲁顿酪氨酸激酶(BTK)抑制剂[伊布替尼、阿可替尼])的耐药。
关键数值与推荐
- 治疗选择范围从传统化学免疫治疗和干细胞移植(SCT)到针对BTK(共价和非共价)、Bcl2、ROR1的靶向治疗、细胞治疗如抗CD19嵌合抗原受体治疗(CAR-T),以及最近针对CD19和CD20的双特异性抗体。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The field of mantle cell lymphoma (MCL) has witnessed remarkable progress due to relentless advances in molecular pathogenesis, prognostication, and newer treatments. MCL consists of a spectrum of clinical subtypes. Rarely, atypical cyclin D1-negative MCL and in situ MCL neoplasia are identified. Prognostication of MCL is further refined by identifying somatic mutations (such as TP53, NSD2, KMT2D), methylation status, chromatin organization pattern, SOX-11 expression, minimal residual disease (MRD), and genomic clusters. Lymphoid tissue microenvironment studies demonstrated the role of B-cell receptor signaling, nuclear factor kappa B (NF-kB), colony-stimulating factor (CSF)-1, the CD70-SOX-11 axis. Molecular mechanism of resistance, mutation dynamics, and pathogenic pathways (B-cell receptor (BCR), oxidative phosphorylation, and MYC) were identified in mediating resistance to various treatments (bruton tyrosine kinase (BTK) inhibitors [ibrutinib, acalabrutinib]. Treatment options range from conventional chemoimmunotherapy and stem cell transplantation (SCT) to targeted therapies against BTK (covalent and noncovalent), Bcl2, ROR1, cellular therapy such as anti-CD19 chimeric antigen receptor therapy (CAR-T), and most recently bispecific antibodies against CD19 and CD20. MCL patients frequently relapse. Complex pathogenesis and the management of patients with progression after treatment with BTK/Bcl2 inhibitors and CAR-T (triple-resistant MCL) remain a challenge. Next-generation clinical trials incorporating newer agents and concurrent translational and molecular investigations are ongoing.
引用
- Jain P, Wang ML. Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. Am J Hematol. 2022. PMID: 35266562. doi:10.1002/ajh.26523
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。